First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer

BACKGROUND: Death receptor 5 (DR5) is a promising therapeutic target for cancer therapy. However, many clinical trials of DR5 agonists failed to show significant therapeutic efficacy in patients with cancer. The study aimed to investigate the feasibility of using (89)Zr-CTB006 positron emission tomo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shujing, Zhu, Hua, Li, Yingjie, Ding, Jin, Wang, Feng, Ding, Lixin, Wang, Xinyu, Zhao, Jun, Zhang, Yan, Yao, Yunfeng, Zhou, Tong, Li, Nan, Wu, Aiwen, Yang, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728342/
https://www.ncbi.nlm.nih.gov/pubmed/34301815
http://dx.doi.org/10.1136/jitc-2021-002926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8728342/
https://www.ncbi.nlm.nih.gov/pubmed/34301815
http://dx.doi.org/10.1136/jitc-2021-002926

Ejemplares similares